- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Noelle Sunstrom and the Potential Growth for NeuClone
Noelle Sunstrom, CEO and founder of NeuClone, of Redfern, Australia, discusses the company's future US market prospects and its plans to differentiate from other biosimilar developers.
Looking through its robust pipeline of biosimilars, it’s no surprise that Redfern, Australia-based company NeuClone is on its way to becoming a significant player in the biosimilar industry. To date, the company has disclosed information on 6 of its products, 2 of which are being tested in phase 1 clinical trials and an additional 14 are in earlier-stage development. Although market launches may still be years away, NeuClone is definitely gearing up to show the world what it's made of. We spoke with Noelle Sunstrom, CEO and founder of NeuClone, to discuss the company’s outlook on coming to the US market and how it plans to distinguish itself from the competition.
To learn more about NeuCone, visit neuclone.com.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals
February 9th 2025In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA approvals, patent disputes, and biosimilar market trends shaping the health care landscape.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
